Adenovirus-mediated transfer of genes to the lung

Abstract

The present invention relates, in general, to a adenovirus mediated transfer of genes to the lung. In particular, the present invention relates to a method of recombinant, replication-deficient adenovirus mediated transfer of desired genes to the lung whereby desired proteins of interest are produced for local and/or systemic use.

What is claimed is:  
     
         1 . A method of producing a biologically active protein in a lung of an animal, comprising: 
 administering to the lung of said animal a replication deficient adenovirus comprising a DNA segment encoding said protein and under conditions such that said DNA segment is expressed and said protein thereby produced.    
     
     
         2 . The method according to  claim 1 , wherein said protein is a therapeutic protein.  
     
     
         3 . The method according to  claim 1 , wherein said protein is a coagulation factor, a pituitary hormone, a peptide hormone, a lymphokine, a cytokine, a tumor suppressor protein, a hematologic growth factor, a receptor agonist, or a receptor antagonist.  
     
     
         4 . The method according to  claim 1 , wherein said protein is selected from the group consisting of α1-antitrypsin, erythropoeitin, sector VIII, growth hormone, tumor necrosis binding protein, interleukin-1 receptor antagonist, interferon γ, interferon α, and insulin.  
     
     
         5 . The method according to  claim 1 , wherein said adenovirus is Ad-α1AT.  
     
     
         6 . The method according to  claim 1 , wherein said animal is a mammal, avian or fish.  
     
     
         7 . The method according to  claim 6 , wherein said mammal is selected from the group consisting of human, pig, sheep, cattle, horse, cat, and dog.  
     
     
         8 . The method according to  claim 7 , wherein said bird is a chicken.  
     
     
         9 . A method of treating cystic fibrosis in a patient comprising: 
 administering to the lung of said patient a replication deficient adenovirus comprising a DNA segment encoding a cystic fibrosis transmembrane conductance regulator and under conditions such that said DNA segment is expressed and said regulator thereby produced.    
     
     
         10 . A method of treating α1-antitrypsin deficiency in a patient comprising: 
 administering to the lung of said patient a replication deficient adenovirus comprising a DNA segment encoding α1-antitrypsin and under conditions such that said DNA segment is expressed and said α1-antitrypsin thereby produced.  
 
     
     
         11 . A pharmaceutical composition comprising: 
 A replication deficient adenoviral construct comprising at least one DNA segment encoding for a therapeutic protein and    a pharmaceutically acceptable diluent, carrier, or excipient.    
     
     
         12 . A pharmaceutical composition comprising: 
 a replication deficient adenovirus construct comprising a DNA segment encoding a cystic fibrosis transmembrane conductance regulator and    a pharmaceutically acceptable diluent, carrier, or excipient.    
     
     
         13 . A pharmaceutical composition comprising: 
 a replication deficient adenovirus construct comprising a DNA segment encoding α1-antitrypsin and    a pharmaceutically acceptable diluent, carrier, or excipient.    
     
     
         14 . A kit comprising: 
 i) a pharmaceutical composition selected from  claim 11 ,  12 , or  13 .